Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Karpf

Showing results (101-110 of 105) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 105 results.
Thrombosis Research|March 25, 2011
Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIaDitte M Karpf, Brit B Sørensen, Mette B Hermit, et al.
Journal of Thrombosis and Haemostasis : JTH|March 28, 2018
Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction modelF Rode, K Almholt, M Petersen, et al.
Journal of Thrombosis and Haemostasis : JTH|December 8, 2018
Factor VIII with a 237 amino acid B-domain has an extended half-life in F8-knockout miceE Bloem, D M Karpf, P L Nørby, et al.
Archives of Internal Medicine|January 13, 1997
The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort studyM J Fine, L J Hough, A R Medsger, et al.
Blood|January 22, 2013
A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice modelsHenning R Stennicke, Marianne Kjalke, Ditte M Karpf, et al.
Pageof 11

Showing results (101-110 of 105) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 105 results.
Thrombosis Research|March 25, 2011
Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIaDitte M Karpf, Brit B Sørensen, Mette B Hermit, et al.
Journal of Thrombosis and Haemostasis : JTH|March 28, 2018
Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction modelF Rode, K Almholt, M Petersen, et al.
Journal of Thrombosis and Haemostasis : JTH|December 8, 2018
Factor VIII with a 237 amino acid B-domain has an extended half-life in F8-knockout miceE Bloem, D M Karpf, P L Nørby, et al.
Archives of Internal Medicine|January 13, 1997
The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort studyM J Fine, L J Hough, A R Medsger, et al.
Blood|January 22, 2013
A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice modelsHenning R Stennicke, Marianne Kjalke, Ditte M Karpf, et al.
Pageof 11